… The understanding of IPF pathogenesis has significantly improved over the last two decades,
thus changing the approach to drug development. The previous paradigm considered IPF …

… In this context, different models of lung fibrosis have been developed over the years that
mimic only few features of IPF. The most common of them is induced by intratracheal instillation …

… Traditionally, pharmaceutical development starts with the selection of scientifically robust …
and variable influence by the environment, drug discovery tools commonly used to select and …

… sections, we have attempted to explain the role and mechanism of these signaling
pathways in the pathophysiology of IPF and how they can be manipulated for drug discovery. …

… Pulmonary fibrosis includes several lung disorders characterized by progressive fibrosis, of
which idiopathic pulmonary fibrosis (IPF) is a particularly severe form with a median survival …

… outlining potential new idiopathic pulmonary fibrosis (IPF) … involved in the development of
idiopathic pulmonary fibrosis … The three drugs in most advanced development are covered …

… Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic … Potential etiological factors
associated with the development … ] led to development of severe pulmonary fibrosis in animal …

… Another important challenge to clinical drug development has been finding efficient, informative
end points for early-phase clinical trials. While the default end point has been change in …

… (IPF) is a progressive and debilitating, scarring lung disease with … Novel drugs currently in
development for pulmonary fibrosis … and considers the challenges for future drug development. …

… There may be at least two different pathogenetic mechanisms for the development of
pulmonary fibrosis. First, the inflammatory pathway that mediates drug-induced ILDs, occupation/…